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Summary 
 
Background:  
Magnetic resonance enterography (MRE) can measure small bowel (SB) motility, 
reduction in which reflects inflammatory burden in Crohn’s Disease (CD). However, it 
is unknown if motility improves with successful treatment.  
 
Aims:  
To determine if changes in segmental SB motility reflect response to anti-TNFα 
therapy after induction and longer term. 
 
Methods:  
46 patients (median 29 years,19 females) underwent MRE before anti-TNFα 
treatment; 35 identified retrospectively underwent repeat MRE after median 55 
weeks of treatment and 11 recruited prospectively after median 12 weeks. 
Therapeutic response was defined by physician global assessment (retrospective 
group) or a ≥3 point drop in the Harvey-Bradshaw Index (prospective group), C-
reactive protein (CRP) and the MaRIA score. Two independent radiologists 
measured motility using an MRE image-registration algorithm. We compared motility 
changes in responders and non-responders using the Mann-Whitney test. 
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Results:  
Anti-TNFα responders had significantly greater improvements in motility 
(median=73.4% increase from baseline) than non-responders (median=25% 
reduction, p<0.001). Improved MRI-measured motility was 93.1% sensitive (95%CI 
78.0-98.1%) and 76.5% specific (95%CI 52.7-90.4%) for anti-TNFα response. 
Patients with CRP normalization (<5mg/L) had significantly greater improvements in 
motility (median=73.4% increase) than those with persistently elevated CRP 
(median=5.1%, p=0.035). Individuals with post-treatment MaRIA scores of <11 had 
greater motility improvements (median=94.7% increase) than those with post-
treatment MaRIA score >11 (median 15.2% increase, p=0.017).  
 
Conclusions:  
Improved MRI-measured SB motility accurately detects response to anti-TNFα 
therapy for CD, even as early as 12 weeks. Motility MRI may permit early 
identification of non-response to anti-TNFα agents, allowing personalized treatment. 
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Introduction 
 
Crohn’s disease (CD) treatment has advanced significantly with the availability of 
monoclonal antibodies (mAbs) directed against tumor necrosis factor alpha (TNFα), 
since they reduce symptoms, improve quality of life and increase mucosal healing in 
patients with severe disease[1]. Approximately 15-30% of patients with CD will 
require anti-TNFα mAbs[1] but only a proportion achieve a clinically meaningful 
response[2]; approximately 10-30% fail induction and a further 20-50% will have lost 
response by one year[3]. Monitoring therapeutic response is problematic because no 
single test is perfect. Clinical indices such as the Crohn’s disease activity index 
(CDAI) have been criticized as subjective, non-specific, cumbersome and poorly-
reproducible[4]. Biochemical measures are often non-specific for CD and endoscopy 
is both invasive and cannot assess transmural disease. A non-invasive technique 
that reliably detects therapeutic response at an early stage would be a major clinical 
advance, as it would allow timely triage of non-responders to an alternative 
therapeutic strategy; whether by dose escalation, switching to an alternate drug 
class, or via surgical intervention. 
 
Magnetic resonance enterography (MRE) is widely disseminated and is 
recommended by consensus guidelines as a first-line test for the diagnosis and 
monitoring of CD[5]. Conventional MRI markers of activity such as wall thickness, 
contrast enhancement and T2 mural signal are useful in staging disease, but 
morphological changes lag behind clinical response to anti-TNFα therapy, limiting 
utility for early response assessment. For example, Van Asshe et al reported 
significant reductions in a morphological MRI activity score only by week 26 after 
infliximab induction and long-term persistence of transmural abnormality on MRE 
despite good clinical response[7]. 
 
Alternatively, software quantification of segmental bowel motility using MRE is 
emerging as a valuable marker of inflammatory activity in CD. MRE-measured 
motility has a consistent negative correlation with endoscopic and histopathologic 
measures of inflammation [8,9] – the greater the inflammatory burden, the larger the 
reduction in segmental motility.  Return of motile function in response to therapy 
could conceivably occur more rapidly than standard morphological changes, since 
motility is determined by both gut structure and its neuronal control; the latter 
potentially responding rapidly. This could aid therapeutic decision-making earlier in 
the patient trajectory. To date there are no published data documenting whether or 
not MRE-derived motility changes improve following successful treatment, and, if so, 
whether this occurs soon after treatment initiation.  
 
We hypothesized that 1) patients responding to anti-TNFα mAbs would have greater 
improvements in MRE-measured segmental small bowel (SB) motility than non-
responders and 2) motility changes in diseased segments occurs rapidly after 
initiation of anti-TNFα treatment, allowing MRE to distinguish responders from non-
responders at an early stage. To investigate these hypotheses, we analysed MRE-
measured segmental SB motility in patients pre- and post-treatment with anti-TNFα 
mAbs. 
 
 
Materials and Methods 
 
To address our two related hypotheses, we analysed two separate groups of 
patients: 1) A retrospective cohort of individuals who had undergone MRE with 
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motility assessment as part of routine clinical care pre- and then again during or post 
medium- and long-term treatment with anti-TNFα mAbs (i.e. late follow-up imaging), 
and (2) A prospective cohort of patients undergoing MRE before and 12 weeks after 
induction with anti-TNFα mAbs (i.e. early follow-up imaging) as part of a wider 
research study.  
 
Ethical considerations 
 
Both the prospective and retrospective studies were approved by the relevant local 
Research Ethics Committees (prospective: NRES Committee South East Coast 
Surrey; 12/LO/1018; retrospective: NRES Committee North West 
London;10/H0720/91) and site Research & Development departments. All 
participants for the prospective study gave informed written consent. 
 
Inclusion and exclusion criteria 
 
Patients were identified for inclusion in the retrospective cohort using a single 
centre’s departmental Inflammatory Bowel Disease (IBD) Biologics audit data, a 
more detailed version of the UK Royal College of Physicians/British Society of 
Gastroenterology National Biologics Audit[10]. All adult (≥18 years) or adolescent 
(≥14 years) patients commenced on either infliximab (IFX; Remicade, Schering-
Plough) or adalimumab (ADA; Humira, AbbVie) for active small bowel or 
ileocolononic CD (Montreal L1, L3 +/- L4 disease[11]) between March 2009 and June 
2014 were cross-referenced against the hospital Radiology Information System. 
Patients were eligible for inclusion if they had completed both (a) a MRE examination 
with SB motility assessment within 1 month of starting anti-TNFα mAbs and (b) a 
follow-up MRE examination with SB motility assessment after initiation of anti-TNFα 
therapy. Those who had not completed SB motility assessment at MRE or who had 
incomplete follow-up data to determine their response to therapy (e.g. failed to attend 
follow-up appointments) were excluded.  
 
For the prospective study, consecutive consenting adult (>18 years) patients who 
were scheduled to commence IFX or ADA for active ileal or ileocolonic (Montreal L1, 
L3 +/- L4 disease) CD on the recommendation of their treating gastroenterologist 
were recruited from a tertiary IBD centre. Patients were excluded if they were unable 
to undergo MRI or were known to have co-existent malignancy, colorectal polyps, 
active infection, celiac disease, an estimated glomerular filtration rate of 
<60ml/min/1.73m2 or pregnancy. Since these patients were also scheduled to 
undergo 18-fluorodeoxyglucose positron emission tomography with computed 
tomography (FDG-PET/CT) as part of a separate study, we also excluded patients 
with a history of cancer or a family history of cancer (defined as malignancy in a first 
degree relative diagnosed at <55 years) and those who had participated in research 
involving ionizing radiation in the preceding 3 years.  
 
For both groups, we recorded (a) disease distribution according the Montreal 
classification (b) disease duration and age at diagnosis (c) history of surgery and (d) 
plasma CRP level at the time of baseline and follow-up MRE. 
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Imaging protocol, analysis and viewing conditions 
 
All patients were scanned on one of 6 MRI units: three of 1.5Tesla field strength 
(Siemens Avanto or Symphony, Siemens Healthcare, Erlangen, Germany) and three 
of 3Tesla field strength (Philips Achieva or Ingenia, Philips Healthcare, Best, The 
Netherlands; or Siemens Verio, Siemens Healthcare, Erlangen, Germany). Patients 
were scanned using the manufacturer’s body coils after ingesting 1.2-2.0L of 2.5% 
mannitol solution. Imaging protocols are available in the Appendix. In brief, the 
motility sequences are acquired during a series of 20 second breath-holds, during 
which multiple coronal MRI images are captured at 1 second intervals in the same 
anatomical position. This thereby generates a series of images depicting motion at a 
frame-rate of 1 image/second (“cine loops”). These 20 second blocks are then 
repeated at multiple positions until the entire small bowel volume has been imaged 
(7-15 blocks according to body habitus).  Subsequently, imaging data were 
anonymized with a study code and copied to a secure central research office for 
processing and analysis.  
 
Motility data were processed and quantified according to a previously published and 
validated method[12]. This uses an optic flow registration algorithm to estimate 
deformation of each frame of a given cine loop from an initial target frame, thereby 
serving as a measure of motility (since we expect deformation of images acquired in 
the same anatomical position to be primarily due to motion). Such motion can be 
quantified by taking the standard deviation of the Jacobian determinant of this 
deformation (quantified in arbitrary units, AU), which has previously been shown to 
correlate with histological inflammation[9]. Motility measurements mainly reflect local 
bowel motion rather than bulk bowel transit times; a typical range for a healthy adult 
is 0.15-0.55 AU in the fasting state[13]. To facilitate analysis, we used a graphical 
user interface (GUI) developed using Matlab (The MathWorks, Inc., Natick, MA; 
Figure 1) which both displays the cine loops and permits the user to define which 
areas of small bowel should be subjected to motility analysis by encompassing them 
in a freehand region of interest (ROI). For each patient, two experienced radiologists 
(BLINDED, 10 years experience of MRE or BLINDED, 7 years experience), aided by 
the designer of the GUI (BLINDED) independently and in separate reading sessions 
drew a polygonal ROI on a single segment of small bowel demonstrating the most 
severe mural thickening on the motility images. The ROI was drawn to include the 
bowel wall and lumen but extra-enteric tissues were excluded (Figure 1). 
Radiologists were blinded to all clinical, demographic and follow-up information 
throughout to avoid bias when defining their ROIs. This process was repeated for the 
post-treatment MRE scans. Care was taken to match the position of the ROI to that 
placed on the pre-treatment images. When placing ROIs, radiologists were blinded to 
all other MRI sequences other than the cine motility block to avoid morphological 
MRI changes biasing their placement (in six cases (two for reader 1, four for reader 
2), limited anatomical correlation was permitted to confirm that the ROI was placed 
on small bowel rather than colon). 
 
A third radiologist (BLINDED, 6 years of experience of MRE) applied a validated 
MRE-based score of CD activity[14] and response to treatment[6], the Magnetic 
Resonance Index of Activity (MaRIA) score, to the segment of bowel selected by the 
two observers by using the formula: 
 
MaRIA = [1.5 x wall thickness(mm)] + [0.02 x relative contrast enhancement] 
 + [5 x oedema] + [10 x ulceration]. 
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Definitions of response to therapy 
 
Independent of the MRE analysis, each patient was classified as either a “responder” 
or a “non-responder” to anti-TNFα therapy. For the retrospective cohort, a physician 
global assessment (PGA) was used[15]. Specifically, an experienced 
gastroenterologist (BLINDED, 20 years experience in gastroenterology) used the 
electronic patient record to review all available clinical data (including outpatient clinic 
letters, biochemistry results including C-reactive protein (CRP), imaging, endoscopy 
and histopathology reports) to define a composite global assessment of response to 
treatment. This judgment was made using information available at the time of the 
follow-up MRE examination, ignoring subsequent data. Patients who had required 
dose escalation, a switch to an alternative biologic agent or colorectal or intestinal 
surgery were considered to be non-responders. For the prospective cohort, response 
was defined as a reduction in Harvey Bradshaw Index of 3 or more points between 
baseline and 3 months after initiation of anti-TNFα therapy, and no requirement for 
dose escalation, a switch to an alternative agent or surgery. Since HBI and the PGA 
are to a degree subjective, we also analysed whether motility improvements were 
seen in patients with normalization of CRP (defined as a reduction from >5mg/L at 
baseline to ≤5mg/L at follow-up, mirroring a post-hoc analysis of the ACCENT-1 
trial[16]) or with improvements in the independently-applied MaRIA score. 
Specifically, based on recent work investigating the MaRIA score as a proxy for ulcer 
healing after medical treatment[6], patients with a follow-up segmental score of <11 
were deemed responders. Finally, we also assessed patients with either endoscopic 
or surgical proof of their eventual response to therapy (judged subjectively by 
BLINDED); to be included in this analysis, patients had to have undergone 
ileocolonoscopy within 3 months of the baseline MRE and either ileocolonoscopy or 
surgery within 3 months of the post-treatment MRE. 
 
Statistical analysis 
 
Data were collated using Microsoft Excel 2011 for Mac (Microsoft Corp, Redmond, 
WA, USA) and analysed using R version 3.0.1 (R Foundation for Statistical 
Computing, Vienna, Austria). Motility data were not normally distributed and therefore 
between-group comparisons for each reader were made by the Mann-Whitney-
Wilcoxon test. Reproducibility of motility scores between readers was assessed 
using the intraclass correlation coefficient and Bland-Altman limits of agreement[17]. 
To determine the optimal cut-point at which a change in motility was associated with 
response to therapy, empirical and smoothed receiver-operating characteristic (ROC) 
curves were constructed using the pROC package for R{Robin, 2011 #646}. 95% 
confidence intervals were computed using the DeLong method for empirical curves 
and using 10,000 bootstrap replicates with the percentile method for smoothed 
curves. ROC curves were constructed for each radiologist and compared using the 
bootstrap method. Summary sensitivity and specificity for response were estimated 
using mean motility scores for both radiologists. To account for possible covariates 
that might confound the association between motility changes and response, we 
performed multilevel logistic regression with response as the outcome variable, mean 
segmental motility as the predictor variable (averaged between radiologists) and age, 
disease duration (in years), distribution (according to the Montreal classification) and 
history of surgery as covariates. Study group (i.e. retrospective or prospective) was 
included as a random intercept term to account for possible clustering effects. For all 
analyses, p<0.05 was taken to represent statistical significance. 
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Results 
 
Baseline clinical data 
40 patients were recruited to the retrospective study (March 2009-June 2014) and 17 
to the prospective study (November 2012-March 2014). Six patients in the 
prospective study and 5 in the retrospective study did not complete motility MRE at 
both timepoints, and hence were excluded from further analysis, leaving 11 patients 
(6 males) and 35 patients (21 males) respectively. No adverse events were recorded. 
Demographics are summarized in Table 1. The prospective group was, on average, 
older than the retrospective group (median age 40 years vs 23 years, p=0.015) and 
more likely to have isolated ileal (L1) disease (prospective: 6/11, 54.5%; 
retrospective: 5/35, 14.3%, p=0.02). Approximately half of the patients in both groups 
had required previous surgery (prospective: 6/11, 54.5%; retrospective: 16/35, 
45.7%, p=0.87). There was no significant difference in baseline or post-treatment 
CRP between the two groups (Table 1). The median time between initiation of anti-
TNFα therapy and follow-up was 55 weeks (range 11.5 to 123 weeks) in the 
retrospective group and 11.6 weeks (range 9.6 to 17.7 weeks) in the prospective 
group. A single patient in the retrospective group underwent follow-up imaging earlier 
than 90 days after initiating anti-TNFα therapy, and a single patient in the prospective 
group underwent follow-up MRE later than 90 days.  
 
Reproducibility of motility measurements 
Motility measurement was possible in all patients for both readers. Overall, there was 
a good association between the two readers’ motility scores at baseline (ICC=0.65, 
p<0.001) and after treatment (ICC=0.71, p<0.001). The mean difference in motility 
scores between readers was 0.0043AU at baseline (Bland-Altman 95% limits of 
agreement=0.22AU) and -0.0062AU after treatment (Bland-Altman 95% limits of 
agreement=0.23AU).  
 
Disease response: Retrospective group 
Overall, based on the PGA, 22/35 (62.9%) patients responded to anti-TNFα 
treatment and 13/35 (37.1%) patients did not. Baseline motility (averaged between 
readers) was not significantly different between the two groups (responders: 
median=0.15AU; non-responders: median=0.21AU, p=0.086, Table 2). Conversely, 
following treatment, motility was significantly greater in responders (median=0.33AU) 
than in non-responders (median=0.23AU, p=0.0086). Accordingly, the change in 
motility between baseline and follow-up examination was significantly greater in 
responders (median absolute change=0.142AU; median percentage change = 
105.8% increase) than non-responders (median absolute change = -0.081AU, 
median percentage change = 25.0% reduction, p=0.0001, Figure 2). Overall, any 
increase in motility between baseline and follow-up was 95.5% sensitive (95%CI 
78.2-99.8%) and 84.6% specific (95%CI 57.8-95.7%) for distinguishing response 
from non-response. ROC AUC was 93.0% (95%CI 83.4-100%) for the empirical 
curve and 89.5% (95%CI 80.2-96.6%) for the smoothed curve. The optimal operating 
point for the smoothed curve corresponded to a sensitivity of 84.2% and a specificity 
of 79.1%.  
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Disease response: Prospective group 
A similar proportion of patients responded to therapy as in the retrospective group: 
7/11 (63.6%) patients were responders and 4/11 (36.4%) were non-responders. 
There was no significant difference in baseline motility between responders 
(median=0.12AU) and non-responders (median=0.17AU, p=0.97, Table 2). Changes 
in motility between baseline and follow-up MRE examinations were significantly 
greater for responders (median absolute change=0.026AU, median percentage 
change=31.1% increase) than non-responders (median absolute change = -
0.026AU, median percentage change =21.0% reduction, p=0.04, Figure 2). Any 
increase in motility between baseline and follow-up was 85.7% sensitive (95%CI 
48.7-99.3%) and 75% specific (95%CI 30.1-98.7%) for the distinction between 
responders and non-responders, with ROC AUC of 78.6% (95%CI 42.9-100%) for 
the empirical curve and 82.9% (95%CI 67.8-98.4%) for the smoothed curve. The 
optimal operating point for the smoothed curve corresponded to a sensitivity of 
72.8% and a specificity of 78.5%. 
 
When both groups were combined, the same trends were observed (Table 2), with 
no significant difference in baseline motility between responders and non-responders 
(p=0.07) but significantly greater motility in responders after therapy (p=0.005). Pre- 
and post-treatment values of motility, split by reader and clinical outcome, are shown 
in Figure 3. Any increase in motility between baseline and follow-up MRE was 93.1% 
sensitive (95%CI 78.0-98.1%) and 76.5% specific (95%CI 52.7-90.4%) for response. 
Overall, the ROC AUC for an increase in motility between baseline and follow-up 
MRE was 91.5% (95%CI 82.3-100.0%) for the empirical curve and 87.7% (95%CI 
78.5-94.6%) for the smoothed curve, with no significant difference between readers 
(reader 1: ROC AUCsmooth=85.0%, 95%CI 74.7-93.3%, ROC AUCempirical=87.9%, 
95%CI 77.2-98.6%; reader 2: ROC AUCsmooth=84.6%, 95%CI 73.5-92.2%, ROC 
AUCempirical=87.0%, 95%CI 76.1-98.0%, p=0.86, Figure 4).  
  
 
Comparison to changes in CRP 
Five patients (all from the retrospective group) had no CRP measurement at the time 
of follow-up imaging, leaving 41 patients for further analysis. Normalization of CRP 
on treatment (i.e. reduction from >5mg/L pre-therapy to ≤5mg/L at follow-up) 
occurred in 17/41=41.5% of patients. Patients with normalized CRP had a median 
increase in motility of 0.10AU (median percentage change of 73.4%) between 
baseline and follow-up imaging. The 24 of 41 (58.5%) patients without normalization 
of CRP had significantly smaller changes in motility (absolute change of 0.005AU, 
median percentage change of 5.1%, p=0.0035). This remained statistically significant 
after excluding 15 patients with a normal CRP at baseline – the 9 patients with a 
persistently raised CRP at both baseline and follow-up had a median motility change 
of 0.04AU (0.0%), a statistically significant difference from patients with normalized 
CRP on treatment (p=0.005, Figures 5 and 6). 
 
 
Comparison to changes in MaRIA score 
39 patients had MRE acquisitions with correct intravenous contrast enhancement 
timing, permitting measurement of the ileal MaRIA score. There was a statistically 
significant negative correlation between motility and MaRIA scores (i.e. improved 
motility was associated with reduced MaRIA score, r=-0.38, p=0.016, Figure 5). 
Patients with a post-treatment segmental MaRIA score of <11 had significantly 
greater improvements in motility than patients with persistently raised MaRIA scores 
(post-treatment MaRIA<11: median change in motility=0.021AU, a 15.2% increase; 
post-treatment MaRIA≥11: median change in motility=0.17AU, a 94.7% increase, 
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p=0.017, Figure 6). When judged against clinical outcomes of HBI (prospective 
cohort) or PGA (retrospective cohort), responders had greater improvements in 
segmental MaRIA score (median change=8.5 point reduction) than non-responders 
(median change=2.6 point reduction) although the difference was not statistically 
significant (p=0.07). 
 
 
Comparison to endoscopic / histological outcomes 
9 patients had pre-treatment ileocolonoscopy and post-treatment ileocolonoscopy 
(n=7) or surgery (n=2), all in the retrospective study cohort. Within this subset, 
changes in motility were significantly greater in patients who had responded to 
therapy than in non-responders (responders: median motility change=0.14AU, a 
60.3% increase; non-responders: median motility change= -0.13AU, a 25.0% 
decrease, p=0.032, Figure 6).   
 
 
Adjustment for covariates 
Logistic regression confirmed that a greater motility at follow-up MRE was 
significantly associated with response when adjusting for all covariates (OR=1.10, 
95%CI 1.02-1.20, p=0.017). Improved motility between baseline and follow-up was 
even more strongly associated with response (OR=1.24, 95%CI 1.08-1.43, 
p=0.0027) i.e. for each 0.01 AU increase in motility between baseline and follow-up, 
the odds of that patient being a responder increased by 1.24 (Table 3).  
 
Discussion 
 
In this study, we measured MRE-quantified small bowel motility pre- and post 
treatment with anti-TNFα mAbs and found that motility improvements are strongly 
associated with clinical response to therapy, both in the short-term (3 months) and 
longer-term. Overall, an improvement in motility was 93.1% sensitive and 76.5% 
specific for response to treatment. Furthermore, patients with normalization of CRP 
on treatment (a documented predictor of long-term response to anti-TNFα 
treatment[16]), post-treatment MaRIA scores of <11 (a non-invasive marker of ulcer 
healing[6,14]) or endoscopic/surgical proof of response also had improved motility, 
whereas those with persistently abnormal results on these reference standards did 
not. 
 
Motility disturbance in active IBD is well documented for both ulcerative colitis 
(UC)[18,19] and CD[20]. Previous work using MRE has shown not only that motility is 
reduced in active CD, but also that the degree of such reduction is a quantitative 
marker of the severity of enteric inflammation, whether judged by endoscopic, 
histologic or morphological MRE criteria[9,21]. The mechanisms by which reduced 
motility occurs are not well understood. However, active CD is accompanied by 
inflammatory involvement of the submucosal or myenteric plexuses (i.e. plexitis)[22] 
which likely disrupts the normal neuronal control of gut motion. The degree to which 
this dysmotility improves following treatment or remission of CD has been studied 
less, partly because of the relative difficulty and inconvenience of manometric 
measurements. Although the available literature suggests that there are detectable 
small bowel[23] and gastric[24] motility disturbances even in inactive CD, these 
studies compared motility in CD patients with healthy controls rather than within the 
same individual after treatment. We are not aware of any intra-individual 
comparisons of motility pre- and post-treatment in CD. However, unlike manometry-
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based techniques, MRE is both well-tolerated and commonly acquired as part of 
routine clinical practice. Since we have shown here that improvements in MRE-
measured motility have considerable potential as a marker of response to therapy, 
this could be incorporated into current care pathways with relatively little 
inconvenience for patients.  
 
 
The timecourse of symptomatic improvement, mucosal healing and resolution of 
transmural lesions after commencing anti-TNFα therapy have been investigated by 
several prior studies. Clinical improvement (as measured by CDAI) is frequently 
apparent by 2 weeks[25,26]. Mucosal healing can be detected at 10-12 
weeks[27,28]. MRE parameters have been relatively less studied. Recently, when 
using a validated activity index (the MaRIA score) one prospective study found good 
agreement with endoscopic mucosal healing at 12 weeks[6] although the MaRIA 
score itself includes a measure of mucosal ulceration. Previous data evaluating 
transmural disease using MRE suggests a more prolonged time course for changes 
in response to treatment, with complete normalization being rare even at 26 
weeks[7]. In the present study, we found that motility changes occur rapidly after 
treatment initiation; improvements in motility were apparent by 12 weeks, raising the 
possibility that MRE motility assessments may be valuable as an objective marker of 
early disease response.  
 
 
The main limitations of our study relate to the definitions of disease response. We 
used a ≥3-point change in the common clinical scoring system, the HBI, to define 
response to therapy in the prospective study, which correlates well with a 100-point 
change in the Crohn’s Disease Activity Index[29]. However, such changes do not 
capture all elements of response to anti-TNFα therapy and may not necessarily 
directly reflect inflammatory activity. Similarly, in the retrospective study we used a 
physician global assessment definition of response to therapy based on a 
retrospective case review. While this arguably reflects the situation in routine 
practice, has been used previously in the literature[15] and acknowledges that no 
single test or clinical index can define response to therapy in isolation, there is the 
possibility of bias in such a retrospective assessment, although motility 
measurements and response categorisation were made independently of each other 
to mitigate this. Furthermore, our results were consistent across both response 
definitions, and were supported by changes to the inflammatory marker CRP and the 
validated MRE measure of disease activity, the MaRIA score. Additionally, the subset 
of patients with endoscopic or surgical proof of their response status showed the 
same results as the overall cohort, adding weight to the validity of our findings. 
 
The fact that motility MRE showed imperfect agreement with CRP is likely due to the 
limitations of CRP as a marker of response to therapy, particularly since MRE 
showed greater concordance with response as defined by the HBI or the physician 
global assessment. We observed imperfect agreement between response status as 
judged by motility changes and by the MaRIA score. This could be due to our use of 
a segmental rather than global MaRIA score (since we were unable to evaluate the 
colon in the manner described by Rimola et al, which requires a colonic water 
enema). In our study, segmental MaRIA was less sensitive and specific for clinically-
defined response than segmental motility measurements; whether this is due to use 
of segmental rather than global MaRIA, limitations with our composite reference 
standard or a true superiority of motility measurement over MaRIA is speculative. 
Some non-responders may have had fibrostenotic disease, explaining their non-
response to anti-TNFα therapy; such patients may be optimally evaluated by a MRE 
study including delayed contrast-enhanced sequences[30]. 
 11 
 
A further limitation of our study relates to the choice of motility metrics. Although 
mean segmental motility provides an excellent, repeatable and reproducible measure 
of overall bowel motion[31], it does not separately quantify individual measures of 
contractile activity (e.g. contraction frequency and amplitude) or estimate transit 
times. We anticipate that technical developments of motility MRE analysis[21] will 
make such improvements possible in the short term. Finally, the number of patients 
included in this study (particularly the prospective arm) was relatively small; our data 
require confirmation in a larger prospective cohort. 
 
In summary, improvements in MRE-quantified segmental small bowel motility are 
significantly greater in patients who respond to anti-TNFα mAbs than in non-
responders. These improvements can be demonstrated as early as 12 weeks after 
commencing anti-TNFα therapy, suggesting that motility improvements may be 
valuable as an early marker of response to treatment. 
 
Figure legends 
 
Figure 1. 
 
 Example of the graphical user interface used by the radiologist when defining 
diseased small bowel. (A) demonstrates a single frame from a 20-second breath-hold 
cine imaging block over the terminal ileum (arrow), performed prior to anti-TNFα 
treatment. The software computes a parametric map of motility, colour-coded in (B), 
with red denoting greater motion and blue denoting less motion. The radiologist-
drawn ROI in (B) corresponds to an area of low motion, quantified as 0.07 arbitrary 
units (AU). (C) depicts follow-up imaging, with the same part of the small bowel 
(terminal ileum) shown by the arrow. The radiologist-drawn ROI in (D) now 
corresponds to an area of increased motility, measuring 0.34AU. 
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Figure 2. 
 
Boxplots showing absolute change in motility between baseline and follow-up for 
non-responders (N) and responders (R), for the retrospective group, the prospective 
group and both groups combined. All p values are for Mann-Whitney U-test 
comparisons between the two groups. Whiskers show the range.  
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Figure 3. 
 
Stripcharts showing motility data at baseline (Scan 1) and after treatment (Scan 2), 
for both radiologists. The left hand panels depict results for patients who were 
deemed responders to therapy, with non-responders shown in the right hand panels. 
Green dashed lines show patients with motility increase between the two timepoints, 
red dashed lines show patients with motility decrease. 
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Figure 4. 
 
Receiver operating characteristic curves for changes in motility between baseline 
and follow-up to discriminate responders from non-responders for (a) radiologist 1 
and (b) radiologist 2. The optimal operating point is shown as a triangle for the 
empirical curve and a circle for the smoothed curve. Grey shaded region indicates 
95% confidence intervals derived from 10000 bootstrap replicates. 
 
 
 
 
Figure 5. 
 
Scatterplots depicting relationships between pre- and post-treatment motility change 
and (a) change in C-reactive protein (CRP) and (b) change in MaRIA score. Solid 
line = linear regression model, with Pearson correlation coefficient (r) and probability 
(p). Green markers = responders to anti-TNF therapy, red markers = non-
responders, judged using Harvey-Bradshaw Index (prospective cohort) or a 
Physician’s Global Assessment (retrospective cohort). 
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Figure 6. 
 
Boxplots showing percentage change in motility between baseline and follow-up for 
non-responders and responders, as judged by normalized C-reactive protein (CRP, 
left-hand panel), post-treatment MaRIA (middle panel) and endoscopic / surgical 
outcome (right-hand panel). All p values are for Mann-Whitney U-test comparisons 
between the two groups. Whiskers show the range.  
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Tables 
 
 
Table 1.  
Baseline patient demographics 
 
 
 
 
 
 
 
 
 
 
 
  
  Prospective group 
(n=11) 
 
Retrospective group 
(n=35) 
p 
value 
 
Males (%) 
 
  
6 (54.5%) 
 
21 (60%) 
 
1.0 
Median age (range)  40 years (22-57 
years) 
 
23 years (15-65 
years) 
 
0.015 
Median age at diagnosis (range) 
 
31 years (6-44 years) 
 
16 years (6-53 years) 0.060 
Median disease duration (range) 
 
4 years (1-30 years) 
 
5 years (1-31 years) 0.22 
Disease location    
 L1 (%) 6 (54.5%) 8 (22.9%) 0.11 
 L3 (%) 5 (45.5%) 
 
27 (77.1%) - 
Number of previous surgical 
procedures 
   
 0 (%) 6 (54.5%) 16 (45.7%) 0.87 
 1 (%) 4 (36.4%) 8 (22.9%) - 
 2 (%) 1 (9.1%) 8 (22.9%) - 
 3+ (%) 
 
0 (0.0%) 3 (8.6%) - 
Anti-TNF agent    
 Infliximab (%) 5 (45.5%) 22 (62.9%) 0.48 
 Adalimumab (%) 
 
6 (54.5%) 13 (37.1%) - 
Median C-reactive protein (mg/L)    
 Pre treatment (range) 22 (2-32) 15 (1-38) 0.72 
 Post treatment (range) 
 
9 (1-23) 13 (4-30) 0.09 
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Table 2.  
Comparison between baseline, pre- and post-therapy motility for responders and 
non-responders, split by study group. All motility measurements are mean scores for 
both radiologists. 
 
 
 
Retrospective group 
 
 Responders (n=22) 
 
Non-responders 
(n=13) 
p value 
Median baseline motility, 
AU (range) 
 
0.15 (0.044-0.38) 0.21 (0.068-0.51) 0.08 
Median follow-up 
motility, AU (range) 
 
0.33 (0.13-0.72) 0.23 (0.065-0.38) 0.009 
Median change in 
motility, AU (range) 
 
0.14 (-0.007-0.59) -0.081 (-0.24-0.17) 0.0001 
Prospective group 
 
 Responders (n=7) Non-responders 
(n=4) 
 
p value 
Median baseline motility, 
AU (range) 
 
0.12 (0.060-0.30) 0.17 (0.075-0.26) 0.97 
Median follow-up 
motility, AU (range) 
 
0.20 (0.077-0.44) 0.11 (0.07-0.26) 0.16 
Median change in 
motility, AU (range) 
 
0.026 (-0.009-0.20) -0.026 (-0.09-0.045) 0.04 
Both groups combined 
 Responders Non-responders p value 
 
Median baseline motility, 
AU (range) 
 
0.14 (0.044-0.38) 0.26 (0.068-0.51) 0.07 
Median follow-up 
motility, AU (range) 
 
0.29 (0.08-0.72) 0.20 (0.065-0.38) 0.005 
Median change in 
motility, AU (range) 
 
0.13 (-0.09-0.59) -0.078 (-0.24-0.17) 0.0001 
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Table 3. 
Patient factors associated with response to anti-TNF therapy, derived by multilevel 
logistic regression and expressed as odds ratios.  
 
  
Odds ratio (95% CI) 
 
p value 
 
Age (per year) 
 
 
0.97 (0.90-1.05) 
 
0.44 
Disease duration (per year) 0.96 (0.84-1.10) 0.56 
Previous surgery (vs no previous surgery) 0.64 (0.20-2.06) 0.46 
Isolated ileal disease (vs ileocolonic disease) 0.48 (0.05-4.37) 0.52 
Change in motility (per 0.01 unit change) 1.24 (1.08-1.43) 0.0027 
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